Tarsus Pharmaceuticals TARS
NASDAQ TARS
$73.73 -1.73 (-2.29%)
As of: Oct 2, 2026 · 2:31 PM EDT

Tarsus Pharmaceuticals (TARS) Non Operating Interest Expenses (2022 - 2026)

Updated

Tarsus Pharmaceuticals' Non Operating Interest Expenses was $2.16 million in Q2 2026, down 3.8% from $2.24 million a year earlier but up 1.3% from the prior quarter.

Analysis

Tarsus Pharmaceuticals (TARS) Non Operating Interest Expenses (2022 - 2026) Analysis & Trends

On a trailing twelve-month basis, Tarsus Pharmaceuticals' Non Operating Interest Expenses was $8.77 million through Jun 30, 2026, down 4.8% year-over-year; for FY2025, it came in at $8.94 million, up 13.8% from FY2024.

  • Non Operating Interest Expenses has now increased for three consecutive years, with a three-year compound annual growth rate of 59.6% (FY2022 to FY2025).
  • In earlier years, Non Operating Interest Expenses was $7.85 million in FY2024 (+134.6%), $3.35 million in FY2023 (+52.2%) and $2.2 million in FY2022.
  • Quarterly Non Operating Interest Expenses has moved between $316,000 (Q1 2022) and $2.45 million (Q3 2024) over five years.
  • Compared with a year earlier, Non Operating Interest Expenses has declined for four straight quarters, with growth averaging 53.9% over the last eight quarters.
  • The best year-over-year quarter for Non Operating Interest Expenses over five years was Q3 2024 (growth of 185.0%); the worst was Q3 2025 (a decline of 7.2%).
  • Per Business Quant data, TARS's Non Operating Interest Expenses in the three quarters before Q2 2026 was $2.13 million (Q1 2026), $2.21 million (Q4 2025) and $2.27 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 281.00 Mn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -462.00 Mn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -435.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 673.00 Mn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 247.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Tarsus Pharmaceuticals 3.40 Bn 2.35 Bn 161.80 Mn 2.16 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.16 Mn
Mar 31, 2026 2.13 Mn
Dec 31, 2025 2.21 Mn
Sep 30, 2025 2.27 Mn
Jun 30, 2025 2.24 Mn
Mar 31, 2025 2.21 Mn
Dec 31, 2024 2.31 Mn
Sep 30, 2024 2.45 Mn
Jun 30, 2024 2.11 Mn
Mar 31, 2024 983,000.00
Dec 31, 2023 989,000.00
Sep 30, 2023 858,000.00
Jun 30, 2023 815,000.00
Mar 31, 2023 684,000.00
Dec 31, 2022 692,000.00
Sep 30, 2022 633,000.00
Jun 30, 2022 544,000.00
Mar 31, 2022 316,000.00
API Access

Tarsus Pharmaceuticals Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=TARS&period=max&api_key=YOUR_API_KEY